U.S., March 24 -- ClinicalTrials.gov registry received information related to the study (NCT07487883) titled 'Cadherin 3(CDH3)-Targeted PET in Lung Malignant Tumors' on March 02.
Brief Summary: Lung malignant tumors are a significant health threat with high incidence and mortality rates, and molecular imaging is crucial for early diagnosis, staging, prognosis evaluation, and therapeutic efficacy assessment. 18F-FDG PET imaging is widely used, but has limitations. CDH3 is a promising target for tumor-targeted imaging, as it is only expressed in cancerous epithelial cells. A new PET probe, 68Ga-TOI-1, targeting CDH3 has been developed with better affinity and selectivity than previous probes. Preclinical data support its safety and metabolic...